Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | ABL2 | P42684 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10139717 | 0.89 | SRC (0.53) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL19731361 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL6866966 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL357171 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL29503465 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL355610 | 0.85 | GPR119 (0.42) | CYP2C9GPR119 | |
| SCHEMBL357484 | 0.82 | ALDH1A1 (0.48) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL19731353 | 0.82 | SRC (0.60) | SRCEGFRABL1ABL2CYP3A4 | |
| SCHEMBL28928812 | 0.82 | SRC (0.66) | SRCEGFRABL1ABL2MEN1 | |
| SCHEMBL15345425 | 0.82 | SRC (0.59) | SRCEGFRABL1ABL2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | SRC 1364/4885EGFR 648/4885ABL1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.